Mohamad Navab

Dr. Mohamad Navab

Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2011 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
Mohamad NavabMohamad Navab
Mohamad Navab
SRSrinivasa T. Reddy
Srinivasa T. Reddy
BLBrian J. Van Lenten
Brian J. Van Lenten
AFAlan M. Fogelman
Alan M. Fogelman

1 June 2004 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
Mohamad NavabMohamad Navab
Mohamad Navab
GAG. M. Ananthramaiah
G. M. Ananthramaiah
SRSrinivasa T. Reddy
Srinivasa T. Reddy
BLBrian J. Van Lenten
Brian J. Van Lenten
BABenjamin J. Ansell
Benjamin J. Ansell
AFAlan M. Fogelman
Alan M. Fogelman
For more than two decades, there has been continuing evidence of lipid oxidation playing a central role in atherogenesis. The oxidation hypothesis of atherogenesis has evolved to focus on specific proinflammatory oxidized phospholipids that result from the oxidation of LDL phospholipids containing arachidonic acid and that are recognized by the innate immune system in animals and humans. These oxidized phospholipids are largely generated by potent oxidants produced by the lipoxygenase and myeloperoxidase pathways. The failure of antioxidant vitamins to influence clinical outcomes may have many explanations, including the inability of vitamin E to prevent the formation of these oxidized phospholipids and other lipid oxidation products of the myeloperoxidase pathway. Preliminary data suggest that the oxidation hypothesis of atherogenesis and the reverse cholesterol transport hypothesis of atherogenesis may have a common biological basis.

22 January 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
Mohamad NavabMohamad Navab
Mohamad Navab
GAG.M. Anantharamaiah
G.M. Anantharamaiah
SHSusan Hama
Susan Hama
DGDavid W. Garber
David W. Garber
MCManjula Chaddha
Manjula Chaddha
AFAlan M. Fogelman
Alan M. Fogelman
When apolipoprotein A-I mimetic peptides synthesized from either D- or L-amino acids were given orally to LDL receptor-null mice, only the peptide synthesized from D-amino acids was stable in the circulation and enhanced the ability of HDL to protect LDL against oxidation. The peptide synthesized from L-amino acids was rapidly degraded and excreted in the urine. When a peptide synthesized from D-amino acids (D-4F) was administered orally to LDL receptor-null mice on a Western diet, lesions decreased by 79%. When added to the drinking water of apoE-null mice, D-4F decreased lesions by approximately 75% at the lowest dose tested (0.05 mg/mL). The marked reduction in lesions occurred independent of changes in total plasma or HDL-cholesterol.

29 June 2004 in Circulation
Verified
Journal Article
Closed access
PDF file
Mohamad NavabMohamad Navab
Mohamad Navab
GAG.M. Anantharamaiah
G.M. Anantharamaiah
SRSrinivasa T. Reddy
Srinivasa T. Reddy
SHSusan Hama
Susan Hama
GHGreg Hough
Greg Hough
AFAlan M. Fogelman
Alan M. Fogelman
Background— These studies were designed to determine the mechanism of action of an oral apolipoprotein (apo) A-I mimetic peptide, D-4F, which previously was shown to dramatically reduce atherosclerosis in mice. Methods and Results— Twenty minutes after 500 μg of D-4F was given orally to apoE-null mice, small cholesterol-containing particles (CCPs) of 7 to 8 nm with pre-β mobility and enriched in apoA-I and paraoxonase activity were found in plasma. Before D-4F, both mature HDL and the fast protein liquid chromatography fractions containing the CCPs were proinflammatory. Twenty minutes after oral D-4F, HDL and CCPs became antiinflammatory, and there was an increase in HDL-mediated cholesterol efflux from macrophages in vitro. Oral D-4F also promoted reverse cholesterol transport from intraperitoneally injected cholesterol-loaded macrophages in vivo. In addition, oral D-4F significantly reduced lipoprotein lipid hydroperoxides (LOOH), except for pre-β HDL fractions, in which LOOH increased. Conclusions— The mechanism of action of oral D-4F in apoE-null mice involves rapid formation of CCPs, with pre-β mobility enriched in apoA-I and paraoxonase activity. As a result, lipoprotein LOOH are reduced, HDL becomes antiinflammatory, and HDL-mediated cholesterol efflux and reverse cholesterol transport from macrophages are stimulated.

1 August 2001 in Journal of Lipid Research
Verified
Journal Article
Open access
Mohamad NavabMohamad Navab
Mohamad Navab
SHSusan Y. Hama
Susan Y. Hama
GHGreg P. Hough
Greg P. Hough
GSGanesamoorthy Subbanagounder
Ganesamoorthy Subbanagounder
SRSrinivasa T. Reddy
Srinivasa T. Reddy
AFAlan M. Fogelman
Alan M. Fogelman
We have developed a novel and rapid cell-free assay of the ability of HDL to prevent the formation of or inactivate oxidized phospholipids. HDL was tested for its ability to inhibit the oxidation of LDL, or inhibit the oxidation of l-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) by hydroperoxyoctadecadienoic acid (HPODE), or inactivate oxidized PAPC (Ox-PAPC). In each case the fluorescent signal generated in the presence of the test substances and the test HDL was determined. As little as 2.5 microg of normal human HDL cholesterol significantly inhibited the fluorescent signal generated by Ox-PAPC; results did not differ regardless of whether the HDL was prepared by gel electrophoresis, fast protein liquid chromatography, or dextran sulfate precipitation. HDL from each of 27 patients with coronary atherosclerosis failed to inhibit the fluorescent signal generated by a control LDL, whereas HDL from each of 31 matched normal subjects with the same levels of HDL cholesterol significantly inhibited the signal. Results from an established cell-based assay (Navab, M., S. Hama, J. Cooke, G. M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K. F. Faull, S. T. Reddy, N. E. Miller, and A. M. Fogelman. 2000. J. Lipid Res. 41: 1481-1494) were identical. HDL from the patients also failed to inhibit the fluorescent signal generated from PAPC plus HPODE (10 of 10 patients) whereas HDL from matched controls (8 of 8 patients) significantly inhibited the fluorescent signal. We conclude that this new assay has the potential to allow widespread testing of the hypothesis that HDL that is dysfunctional in preventing the formation or inactivating oxidized phospholipids may play an important role in the development of atherosclerosis.

1 July 2005 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
Mohamad NavabMohamad Navab
Mohamad Navab
GAG.M. Anantharamaiah
G.M. Anantharamaiah
SRSrinivasa T. Reddy
Srinivasa T. Reddy
SHSusan Hama
Susan Hama
GHGreg Hough
Greg Hough
AFAlan M. Fogelman
Alan M. Fogelman
Despite identical amino acid composition, differences in class A amphipathic helical peptides caused by differences in the order of amino acids on the hydrophobic face results in substantial differences in antiinflammatory properties. One of these peptides is an apolipoprotein A-I (apoA-I) mimetic, D-4F. When given orally to mice and monkeys, D-4F caused the formation of pre-β high-density lipoprotein (HDL), improved HDL-mediated cholesterol efflux, reduced lipoprotein lipid hydroperoxides, increased paraoxonase activity, and converted HDL from pro-inflammatory to antiinflammatory. In apolipoprotein E (apoE)-null mice, D-4F increased reverse cholesterol transport from macrophages. Oral D-4F reduced atherosclerosis in apoE-null and low-density lipoprotein (LDL) receptor-null mice. In vitro when added to human plasma at nanomolar concentrations, D-4F caused the formation of pre-β HDL, reduced lipoprotein lipid hydroperoxides, increased paraoxonase activity, and converted HDL from pro-inflammatory to antiinflammatory. Physical-chemical properties and the ability of various class A amphipathic helical peptides to activate lecithin cholesterol acyltransferase (LCAT) in vitro did not predict biologic activity in vivo. In contrast, the use of cultured human artery wall cells in evaluating these peptides was more predictive of their efficacy in vivo. We conclude that the antiinflammatory properties of different class A amphipathic helical peptides depends on subtle differences in the configuration of the hydrophobic face of the peptides, which determines the ability of the peptides to sequester inflammatory lipids. These differences appear to be too subtle to predict efficacy based on physical-chemical properties alone. However, understanding these physical-chemical properties provides an explanation for the mechanism of action of the active peptides.